BrudyGlauco (DHA and citicoline) for people with glaucoma
Official title: Evaluation of the Effect of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
Run by Institut Catala de Retina · NCT07322965 · Data updated 2026-11-12
This trial will test whether taking BrudyGlauco (DHA plus citicoline) for 12 months helps preserve visual field in adults aged 50–75 with glaucoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 75 Years |
| Sex | All |
| Enrollment | 108 (estimated) |
| Sponsor | Institut Catala de Retina Academic / other |
| Locations | 2 sites (Barcelona, Barcelona and 1 other locations) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | April 30, 2027 |
| Study ends | May 30, 2027 |
| Registry record updated | January 14, 2026 |
| Trial ID | NCT07322965 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 50–75 years old with chronic glaucoma and both structural and functional evidence of optic nerve damage who have at least four reliable prior visual field tests.
✕Probably not a fit
Patients outside the 50–75 age range, those who recently used vitamin or nutraceutical supplements, or those with neurological or retinal conditions, advanced cataract, or current pregabalin treatment are less likely to be eligible or to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled, multicenter trial that gives participants either BrudyGlauco or a matching placebo for 12 months. The main outcome is change in visual field function, with additional monitoring of safety, tolerance, and treatment adherence. Investigators will collect DHA biomarkers using dry blood spot analysis and perform regular ophthalmologic exams and visual field testing, with an interim analysis at six months. Participants are recruited at ophthalmology centers in Barcelona and the study selects the eye with worse mean deviation when both eyes qualify.
Why it matters
Potential benefit: If effective, BrudyGlauco could slow visual field loss by protecting the optic nerve, potentially preserving vision and quality of life.
How similar studies have gone: Some smaller clinical and observational studies have reported modest benefits from citicoline on visual function in glaucoma, while evidence for DHA alone is more limited and mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria: Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography. Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field. 2. At least 4 reliable visual field (VF) tests before study enrollment. 3. Age between 50 and 75 years. 4. If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye. Exclusion Criteria: 1. Use of any vitamin or nutraceutical supplement in the month prior to screening. 2. Any condition that could alter visual field testing, including: Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields. 3. Hypersensitivity to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline). 4. Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study. 5. Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.
Where it's running
-
Institut Català de Retina
Barcelona, Barcelona, Spain Recruiting -
Hospital del Mar | Centre Esperança
Barcelona, Barcelona, Spain Not yet recruiting
Study contacts
- Study coordinator: Alfonso Antón Lopez Antón Lopez, Prof MD PhD
- Email: alfonso.anton@icrcat.com
- Phone: +34 93 4340553
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating oral semaglutide for treating open-angle glaucoma
This study is testing if a daily pill called semaglutide can help improve vision in people with open-angle glaucoma.
-
Pregabalin eye drops vs timolol eye drops for open-angle glaucoma or ocular hypertension
A doctor-led study tests whether pregabalin eye drops (TB0001) work as well as timolol eye drops to lower eye pressure in adults with glaucoma or high eye pressure.
-
Balance training for people with glaucoma
A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.
-
Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma
In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.
-
Comparison of FT-1000 non-contact tonometry with Goldmann applanation tonometry in glaucoma patients
This study tests whether the FT-1000 non-contact tonometer gives measurements that agree with the Goldmann applanation tonometer in adults with glaucoma.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.